2. Metabolic Enzyme/Protease Immunology/Inflammation Anti-infection
  3. Thrombin Interleukin Related RSV
  4. Bivalirudin TFA

Bivalirudin TFA, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin TFA inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin TFA also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin TFA can be used for the research of thrombotic diseases and others.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

Bivalirudin TFA

Bivalirudin TFA Chemical Structure

CAS No. : 1191386-55-6

Size Price Stock Quantity
5 mg In-stock
10 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 8 publication(s) in Google Scholar

Other Forms of Bivalirudin TFA:

Bivalirudin TFA Related Antibodies

Top Publications Citing Use of Products

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Bivalirudin TFA, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin TFA inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin TFA also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin TFA can be used for the research of thrombotic diseases and others[1][2][3][4].

IC50 & Target[2]

IL-6

 

IL-5

 

In Vitro

Bivalirudin (30 μg/mL; 10 min) TFA inhibits Thrombin (HY-114164)-induced S1PR2 upregulation and endothelial hyperpermeability, and reverses the abnormal distribution of cytoskeletal proteins and β-catenin in HUVECs[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Bivalirudin TFA Related Antibodies

Western Blot Analysis[1]

Cell Line: HUVECs treated Thrombin (HY-114164)
Concentration: 30 μg/mL
Incubation Time: 10 min
Result: Inhibited the level of S1PR2.
In Vivo

Bivalirudin (2 mg/kg; intravenous injection; every other day; 2 weeks) TFA exhibits antiviral activity against respiratory syncytial virus in neonatal C57BL/6 mice[2].
Bivalirudin (2 mg/kg; intravenous injection; single dose) TFA inhibits thrombosis in mice[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 mice aged 5-7 days old treated respiratory syncytial virus (RSV)[2]
Dosage: 2 mg/kg
Administration: Intravenous injection; every other day; 2 weeks
Result: Significantly reduced cellular infiltration, inflammatory cytokines (e.g., IL-5, IL-6, CXCL1), and abnormal clotting parameters (e.g., D-dimer, soluble thrombomodulin) in RSV-infected lungs.
Normalized viral copy numbers and reversed histopathological changes such as nuclear pyknosis in pneumocytes.
Animal Model: P2Y12-- and WT mice with thrombosis induced by perfusion through type III collagen- or tissue factor-coated capillary chambers, and P2Y12+- mice with mesenteric artery injury induced by 12.5% FeCl3 solution[3]
Dosage: 2 mg/kg
Administration: Intravenous injection; single dose
Result: Significantly inhibited thrombus volume in P2Y12-- mice in the type III collagen-induced thrombosis model but had no significant effect in wild-type mice.
Inhibited thrombosis in both WT and P2Y12-- mice in the tissue factor-induced thrombosis model.
Delayed the time of thrombus appearance and vessel occlusion, but could not completely prevent vessel occlusion in wild-type mice in the FeCl3-induced mesenteric artery injury model in P2Y12+- mice.
Clinical Trial
Molecular Weight

2294.34

Formula

C98H138N24O33.C2HF3O2
CAS No.
Appearance

Solid

Color

White to off-white

Sequence

{d-Phe}-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu
Sequence Shortening

{d-Phe}-PRPGGGGNGDFEEIPEEYL
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Sealed storage, away from moisture and light

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (43.59 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : ≥ 50 mg/mL (21.79 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 0.4359 mL 2.1793 mL 4.3586 mL
5 mM 0.0872 mL 0.4359 mL 0.8717 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation

Purity: 99.89%

SDS (252 KB)

COA (242 KB) RP-HPLC (111 KB) Elemental Analysis Report (100 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O / DMSO 1 mM 0.4359 mL 2.1793 mL 4.3586 mL 10.8964 mL
5 mM 0.0872 mL 0.4359 mL 0.8717 mL 2.1793 mL
10 mM 0.0436 mL 0.2179 mL 0.4359 mL 1.0896 mL
15 mM 0.0291 mL 0.1453 mL 0.2906 mL 0.7264 mL
20 mM 0.0218 mL 0.1090 mL 0.2179 mL 0.5448 mL
DMSO 25 mM 0.0174 mL 0.0872 mL 0.1743 mL 0.4359 mL
30 mM 0.0145 mL 0.0726 mL 0.1453 mL 0.3632 mL
40 mM 0.0109 mL 0.0545 mL 0.1090 mL 0.2724 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Bivalirudin TFA Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Bivalirudin1191386-55-6ThrombinInterleukin RelatedRSVILRespiratory syncytial viruspeptideanticoagulantanticoagulationinvasivecardiologypercutaneouscoronaryplateletsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Bivalirudin TFA
Cat. No.:
HY-15664
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.